Hepta
Detect, Monitor, and Enable Effective Treatment for Metabolic Disease
- Headquarters
- San Francisco, California
- Employees
- 1–10
- Founded
- 2024
- Business Model
- B2B
- Website
- hepta.bio
- Total Funding
- $7.0M
- Last Round
- $6.7M SeedNov 2025
About
Hepta is an AI-native liquid biopsy company focused on non-invasive diagnostics for metabolic liver disease. Its platform interprets epigenetic patterns in cell-free DNA from a standard blood draw to reveal liver biology, enabling earlier detection and treatment of MASH (metabolic dysfunction-associated steatohepatitis). Founded by former Illumina, GRAIL, and Google leaders, Hepta is headquartered in San Francisco.
Sign up to view funding chart
Create a free account to see funding visualizations and detailed round data.
Create Free AccountFunding History
Sign up to view funding details
Create a free account to see full funding history, valuations, and investor participation.
Create Free Account